MA40534A - Inhibiteurs de mk2 et leurs utilisations - Google Patents

Inhibiteurs de mk2 et leurs utilisations

Info

Publication number
MA40534A
MA40534A MA040534A MA40534A MA40534A MA 40534 A MA40534 A MA 40534A MA 040534 A MA040534 A MA 040534A MA 40534 A MA40534 A MA 40534A MA 40534 A MA40534 A MA 40534A
Authority
MA
Morocco
Prior art keywords
inhibitors
compositions
compounds
methods
relates
Prior art date
Application number
MA040534A
Other languages
English (en)
Other versions
MA40534B1 (fr
Inventor
Matthew David Alexander
Claudio Chuaqui
John Malona
Joseph John Mcdonald
Yike Ni
Deqiang Niu
Chittari Pabba
Russell C Petter
Juswinder Singh
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of MA40534A publication Critical patent/MA40534A/fr
Publication of MA40534B1 publication Critical patent/MA40534B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des composés, leurs compositions et des méthodes pour les utiliser.
MA40534A 2014-09-17 2015-09-16 Inhibiteurs de mk2 et leurs utilisations MA40534B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31
PCT/US2015/050495 WO2016044463A2 (fr) 2014-09-17 2015-09-16 Inhibiteurs de mk2 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA40534A true MA40534A (fr) 2016-03-24
MA40534B1 MA40534B1 (fr) 2021-04-30

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40534A MA40534B1 (fr) 2014-09-17 2015-09-16 Inhibiteurs de mk2 et leurs utilisations

Country Status (30)

Country Link
US (5) US9458175B2 (fr)
EP (2) EP3912981A1 (fr)
JP (3) JP6556225B2 (fr)
KR (1) KR102457848B1 (fr)
CN (1) CN106998692B (fr)
AU (1) AU2015317741B2 (fr)
BR (1) BR112017005266B1 (fr)
CA (1) CA2961607C (fr)
CL (1) CL2017000576A1 (fr)
CO (1) CO2017003279A2 (fr)
CY (1) CY1124215T1 (fr)
DK (1) DK3193611T3 (fr)
EA (1) EA037299B1 (fr)
EC (1) ECSP17023281A (fr)
ES (1) ES2874561T3 (fr)
HR (1) HRP20210529T1 (fr)
HU (1) HUE054347T2 (fr)
IL (1) IL251051B (fr)
LT (1) LT3193611T (fr)
MA (1) MA40534B1 (fr)
MX (2) MX373341B (fr)
PL (1) PL3193611T3 (fr)
PT (1) PT3193611T (fr)
RS (1) RS62017B1 (fr)
SA (1) SA517381115B1 (fr)
SG (2) SG11201701861RA (fr)
SI (1) SI3193611T1 (fr)
SM (1) SMT202100311T1 (fr)
TW (1) TWI744217B (fr)
WO (1) WO2016044463A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908098A1 (fr) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Inhibiteurs mk2 et utilisations associees
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
US11098057B2 (en) * 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170200A1 (fr) * 2017-03-16 2018-09-20 Celgene Car Llc Composés hétéroaryle utiles en tant qu'inhibiteurs de mk2
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2018170203A1 (fr) 2017-03-16 2018-09-20 Celgene Car Llc Inhibiteurs de mk2, leur synthèse et leurs intermédiaires
EP3596085A4 (fr) * 2017-03-16 2020-11-25 Celgene CAR LLC Analogues deutérés d'inhibiteurs de mk2 et leurs utilisations
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
WO2020072580A1 (fr) * 2018-10-02 2020-04-09 Disc Medicine, Inc. Inhibiteurs de matriptase 2 et leurs utilisations
WO2020236636A1 (fr) * 2019-05-17 2020-11-26 Celgene Car Llc Procédés de traitement d'un trouble médié par mk2
KR20220154094A (ko) * 2020-02-14 2022-11-21 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ulk1/2 억제제를 이용한 단일 및 병용 요법
KR20220153582A (ko) 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 마크로시클릭 ulk1/2 억제제
US20230087078A1 (en) * 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
KR20230044446A (ko) * 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
JP2023550347A (ja) * 2020-11-12 2023-12-01 アクティーヴァ セラピューティクス， インコーポレイテッド 血管漏出障害および内皮バリア障害を処置することにおける使用のためのｍｋ２活性化化合物
CN116670142A (zh) * 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
EP4079855A1 (fr) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Composé et procédé pour la prophylaxie et le traitement de la leucémie
WO2023025298A1 (fr) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 Dérivé de quinolinofurane et son utilisation
EP4464694A4 (fr) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd Dérivé polycyclique contenant de la pyridine, son procédé de préparation et son utilisation
WO2024044731A1 (fr) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Composés diazépino-thiéno-quinoxaline et leur utilisation en thérapie
EP4608401A2 (fr) * 2022-10-27 2025-09-03 Bristol-Myers Squibb Company Inhibiteurs de mk2 et leurs utilisations
JP2026505836A (ja) * 2023-02-07 2026-02-18 セルジーン コーポレーション Ｍｋ２キナーゼ分解剤として有用である化合物および組成物
WO2024229401A2 (fr) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Composés de diazépino-thiéno-quinoxaline et leur utilisation en thérapie
CN121368484A (zh) * 2023-06-26 2026-01-20 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
EP1663204B1 (fr) 2003-08-29 2014-05-07 Exelixis, Inc. Modulateurs c-kit et leurs procedes d'utilisation
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
JP4734346B2 (ja) 2005-02-04 2011-07-27 セノミックス インコーポレイテッド 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用
EP1849781A1 (fr) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Dérivés de 3-Amino-4-hydroxy pyrrolidine, procédé de fabrication et utilisation come medicaments
EP2223925A1 (fr) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
MX2009014247A (es) 2007-07-16 2010-01-28 Novartis Ag Compuestos heterociclicos utiles como inhibidores de mk2.
AU2008317057B8 (en) 2007-10-22 2014-02-13 Merck Sharp & Dohme Corp. Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (fr) 2008-10-20 2010-04-29 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (fr) * 2010-06-04 2011-12-08 The Regents Of The University Of California Méthodes et compositions pour l'inhibition de kinases
EP2508511A1 (fr) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2511273B8 (fr) * 2011-04-15 2019-06-26 Hivih Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
CN104136576B (zh) 2012-02-22 2020-10-16 默克专利股份有限公司 液晶介质
WO2013146963A1 (fr) * 2012-03-28 2013-10-03 武田薬品工業株式会社 Composé hétérocyclique
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
WO2014011902A1 (fr) * 2012-07-11 2014-01-16 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisations
EA201590644A1 (ru) * 2012-09-24 2015-09-30 Клермонт Спиде Способ и система с управляемыми мобильным отправителем доступом к данным и удалением данных
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
WO2014139144A1 (fr) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
CA2908098A1 (fr) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Inhibiteurs mk2 et utilisations associees
WO2015050957A2 (fr) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Traitements du lupus érythémateux systémique
WO2016032882A1 (fr) 2014-08-25 2016-03-03 Stc.Unm Inhibition de mk2 dans le traitement du cancer
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
EP3242886A4 (fr) 2015-01-08 2018-08-29 Moerae Matrix, Inc., Formulation de peptides inhibiteurs de mk2
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2018170200A1 (fr) 2017-03-16 2018-09-20 Celgene Car Llc Composés hétéroaryle utiles en tant qu'inhibiteurs de mk2
WO2018170203A1 (fr) 2017-03-16 2018-09-20 Celgene Car Llc Inhibiteurs de mk2, leur synthèse et leurs intermédiaires
EP3596085A4 (fr) 2017-03-16 2020-11-25 Celgene CAR LLC Analogues deutérés d'inhibiteurs de mk2 et leurs utilisations
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2020236636A1 (fr) 2019-05-17 2020-11-26 Celgene Car Llc Procédés de traitement d'un trouble médié par mk2
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법

Also Published As

Publication number Publication date
US20160075720A1 (en) 2016-03-17
KR102457848B1 (ko) 2022-10-25
CO2017003279A2 (es) 2017-09-29
EP3193611A2 (fr) 2017-07-26
MX373341B (es) 2020-05-26
JP6556225B2 (ja) 2019-08-07
PL3193611T3 (pl) 2021-10-04
EP3193611B1 (fr) 2021-03-24
RS62017B1 (sr) 2021-07-30
BR112017005266B1 (pt) 2022-11-01
EA037299B1 (ru) 2021-03-05
EP3193611A4 (fr) 2018-02-28
CL2017000576A1 (es) 2017-12-01
MA40534B1 (fr) 2021-04-30
IL251051A0 (en) 2017-04-30
KR20170063734A (ko) 2017-06-08
CN106998692A (zh) 2017-08-01
EA201790380A1 (ru) 2017-08-31
IL251051B (en) 2019-11-28
US11584757B2 (en) 2023-02-21
CN106998692B (zh) 2020-09-08
CY1124215T1 (el) 2022-05-27
EP3912981A1 (fr) 2021-11-24
TWI744217B (zh) 2021-11-01
US20170114073A1 (en) 2017-04-27
ECSP17023281A (es) 2017-06-30
WO2016044463A2 (fr) 2016-03-24
CA2961607A1 (fr) 2016-03-24
HUE054347T2 (hu) 2021-08-30
US9458175B2 (en) 2016-10-04
HRP20210529T1 (hr) 2021-08-06
DK3193611T3 (da) 2021-05-10
SI3193611T1 (sl) 2021-08-31
US10577380B2 (en) 2020-03-03
JP2022078315A (ja) 2022-05-24
SA517381115B1 (ar) 2021-03-09
US20210053984A1 (en) 2021-02-25
CA2961607C (fr) 2023-03-28
JP2019194236A (ja) 2019-11-07
US10253040B1 (en) 2019-04-09
MX2020005213A (es) 2020-08-20
WO2016044463A3 (fr) 2016-09-01
US20190375762A1 (en) 2019-12-12
AU2015317741A1 (en) 2017-04-20
BR112017005266A2 (pt) 2017-12-12
US9790235B2 (en) 2017-10-17
JP7375072B2 (ja) 2023-11-07
TW201617351A (zh) 2016-05-16
NZ730603A (en) 2024-02-23
SG10201902326XA (en) 2019-04-29
SMT202100311T1 (it) 2021-07-12
PT3193611T (pt) 2021-05-28
ES2874561T3 (es) 2021-11-05
JP2017529367A (ja) 2017-10-05
SG11201701861RA (en) 2017-04-27
AU2015317741B2 (en) 2020-01-16
LT3193611T (lt) 2021-08-25
MX2017003359A (es) 2017-11-22

Similar Documents

Publication Publication Date Title
MA40534B1 (fr) Inhibiteurs de mk2 et leurs utilisations
EA201891251A1 (ru) Бициклические ингибиторы pad4
MX2022005177A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PH12018500457A1 (en) New phenoxymethyl derivatives
MX2018006148A (es) Inhibidores de cxcr2.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201790173A1 (ru) Антитела, связывающие axl
EA201992177A1 (ru) Композиции на основе нирапариба
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201790184A1 (ru) Пестицидные композиции
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
MA41803A (fr) Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
MA39824A (fr) Composés azole amido-substitués
BR112016027455A2 (pt) moduladores ppar